Publications
All publications can be found on Google Scholar page linked in upper right corner
Optimizing hydroxychloroquine dosing for patients with COVID‐19: an integrative modeling approach for effective drug repurposing
Authors: Maria Garcia‐Cremades, Belen P Solans, Emma Hughes, Jacqueline P Ernest, Erika Wallender, Francesca Aweeka, Anne F Luetkemeyer, Radojka M Savic
Year: 2028
Journal:Clinical Pharmacology & Therapeutics
Development of new tuberculosis drugs: translation to regimen composition for drug-sensitive and multidrug-resistant tuberculosis
Authors: Jacqueline P Ernest, Natasha Strydom, Qianwen Wang, Nan Zhang, Eric Nuermberger, Véronique Dartois, Rada M Savic
Year: 2021
Source: Annual review of pharmacology and toxicology
Lesion penetration and activity limit the utility of second-line injectable agents in pulmonary tuberculosis
Authors: Jacqueline P Ernest, Jansy Sarathy, Ning Wang, Firat Kaya, Matthew D Zimmerman, Natasha Strydom, Han Wang, Min Xie, Martin Gengenbacher, Laura E Via, Clifton E Barry III, Claire L Carter, Radojka M Savic, Véronique Dartois
Year: 2021
Journal: Antimicrobial agents and chemotherapy
Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders
Authors: Bitna Yi, Alam Jahangir, Andrew K Evans, Denise Briggs, Kristine Ravina, Jacqueline Ernest, Amir B Farimani, Wenchao Sun, Jayakumar Rajadas, Michael Green, Evan N Feinberg, Vijay S Pande, Mehrdad Shamloo
Year: 2017
Journal: PLoS One
A rabbit model to study antibiotic penetration at the site of infection for nontuberculous mycobacterial lung disease: macrolide case study
Authors: Firat Kaya, Jacqueline P Ernest, Katherine LoMauro, Martin Gengenbacher, Abdeldjalil Madani, Wassihun Wedajo Aragaw, Matthew D Zimmerman, Jansy P Sarathy, Nadine Alvarez, Isaac Daudelin, Han Wang, Faye Lanni, Danielle M Weiner, Laura E Via, Clifton E Barry III, Kenneth N Olivier, Thomas Dick, Brendan K Podell, Radojka M Savic, Véronique Dartois
Year: 2022
Journal: Antimicrobial agents and chemotherapy
Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses
Authors: Nicholas D Walter, Jackie P Ernest, Christian Dide-Agossou, Allison A Bauman, Michelle E Ramey, Karen Rossmassler, Lisa M Massoudi, Samantha Pauly, Reem Al Mubarak, Martin I Voskuil, Firat Kaya, Jansy P Sarathy, Matthew D Zimmerman, Véronique Dartois, Brendan K Podell, Radojka M Savic, Gregory T Robertson
Year: 2023
Journal: Antimicrobial agents and chemotherapy
Pharmacometrics in tuberculosis: progress and opportunities
Authors: Author E, Author F
Year: 2022
Source:
International Journal of Antimicrobial Agents
Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs
Authors: Jacqueline P Ernest, Janice Jia Ni Goh, Natasha Strydom, Qianwen Wang, Rob C van Wijk, Nan Zhang, Amelia Deitchman, Eric Nuermberger, Rada M Savic
Year: 2023
Journal: European Respiratory Journal
Comparative efficacy of rifapentine alone and in combination with isoniazid for latent tuberculosis infection: a translational pharmacokinetic-pharmacodynamic modeling study
Authors: Kendra K Radtke, Jacqueline P Ernest, Nan Zhang, Nicole C Ammerman, Eric Nuermberger, Robert Belknap, Rosanna Boyd, Timothy R Sterling, Rada M Savic
Year: 2021
Journal: Antimicrobial agents and chemotherapy
Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen
Authors: Natasha Strydom, Jacqueline P Ernest, Marjorie Imperial, Belén P Solans, Qianwen Wang, Rokeya Tasneen, Sandeep Tyagi, Heena Soni, Andrew Garcia, Kristina Bigelow, Martin Gengenbacher, Matthew Zimmerman, Min Xie, Jansy P Sarathy, Tian J Yang, Véronique Dartois, Eric L Nuermberger, Radojka M Savic
Year: 2024
Journal: Nature communications
Optimizing Hydroxychloroquine Dosing for Patients With COVID‐19: An Integrative Modeling Approach for Effective Drug Repurposing
Authors: Garcia‐Cremades Maria, P Solans Belen, Hughes Emma, P Ernest Jacqueline, Wallender Erika, Aweeka Francesca, Luetkemeyer Annie, M Savic Radojka
Year: 2020
Journal: Clin Pharmacol Ther
PREDICTING THE EARLY BACTERICIDAL ACTIVITY (EBA) OF TUBERCULOSIS (TB) DRUGS FOR THE PHASE IIA FIRST-IN-PATIENTS STUDIES.
Authors: N Zhang, N Strydom, Q Wang, J Ernest, E Nuermberger, R Savic
Year: 2020
Conference: CLINICAL PHARMACOLOGY & THERAPEUTICS
LIMITED PENETRATION AND EFFICACY OF AMINOGLYCOSIDES IN LESIONS OF TUBERCULOSIS: A TRANSLATIONAL SITE-OF-ACTION PKPD MODELING STUDY.
Authors: J Ernest, N Strydom, J Sarathy, M Zimmerman, V Dartois, R Savic
Year: 2021
Journal: Journal Twelve
Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy-or hard-to-treat tuberculosis disease
Authors: Nathan Peroutka-Bigus, Elizabeth J Brooks, Michelle E Ramey, Hope D'Erasmo, Jackie P Ernest, Allison A Bauman, Lisa K Woolhiser, Radojka M Savic, Anne J Lenaerts, Bree B Aldridge, Jansy P Sarathy, Gregory T Robertson
Year: 2025
Journal: Antimicrobial Agents and Chemotherapy
Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine Models
Authors: Bernard Ngara, Lorenzo Flori, Rob Christiaan van Wijk, Jacqueline P Ernest, Sandeep Tyagi, Heena Soni, Christoph Hölscher, Kerstin Walter, Julia Dreisbach, Michael Hoelscher, Eric L Nuermberger, Radojka M Savic
Year: 2025
Journal: The Journal of Infectious Diseases
Selection and prioritization of candidate combination regimens for the treatment of tuberculosis
Authors: Natasha Strydom, Rob C van Wijk, Qianwen Wang, Jacqueline P Ernest, Linda Chaba, Ziran Li, Eric L Nuermberger, Radojka M Savic
Year: 2025
Journal: Science Translational Medicine
The kinetics of bedaquiline diffusion in tuberculous cavities opens a window for emergence of resistance
Authors: Annamarie E Bustion, Jacqueline P Ernest, Firat Kaya, Connie Silva, Jansy Sarathy, Landry Blanc, Marjorie Imperial, Martin Gengenbacher, Min Xie, Matthew Zimmerman, Gregory T Robertson, Danielle Weiner, Laura E Via, Clifton E Barry, Radojka M Savic, Véronique Dartois
Year: 2024
Journal: bioRxiv
It's That Time of Year-Give Yourself the Gift of SCIENCE!
Authors: Jacqueline Ernest
Year: 2023
Source: CLINICAL PHARMACOLOGY & THERAPEUTICS
GATIFLOXACIN EXPOSURE IN THE LESION AS TARGET SITE OF GATIFLOXACIN IN A RABBIT MODEL OF TUBERCULOSIS: COMPARISON WITH THE OUTCOMES FROM THE PHASE III OFLOTUB TRIAL.
Authors: L Flori, J Ernest, M Zimmerman, V Dartois, R Savic
Year: 2023
Source: CLINICAL PHARMACOLOGY & THERAPEUTICS
A LESION-CENTRIC AND TARGET-SPECIFIC PKPD MODEL OF PYRAZINOIC ACID IN PATIENTS WITH TUBERCULOSIS
Authors: A Fochesato, J Ernest, V Dartois, R Savic
Year: 2023
Conference: CLINICAL PHARMACOLOGY & THERAPEUTICS
Translating Nonclinical Findings to Prioritize Sterilizing Multi-Drug Regimens for the Treatment of Tuberculosis
Authors: Jacqueline Ernest
Year: 2022
Institution: University of California, San Francisco
Response to “Quantitative Clinical Pharmacology INPUT to SARS‐CoV‐2 Therapeutics Should be Based on Robust Data”
Authors: Maria Garcia‐Cremades, Belen P Solans, Emma Hughes, Jacqueline P Ernest, Erika Wallender, Radojka M Savic
Year: 2020
Journal: Clinical Pharmacology and Therapeutics